Results 71 to 80 of about 6,465,161 (268)

Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study

Journal of Cardiothoracic Surgery
Background Combining pemetrexed with bevacizumab may have some potential in improving the efficacy in patients with non-small-cell lung cancer (NSCLC), and this meta-analysis aims to explore the impact of pemetrexed addition to bevacizumab on treatment ...
Wei Fang, Xingqiao Peng, Qun Zhou
doaj   +1 more source

Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study

BMC Cancer, 2020
Background The purpose of this study was to assess the efficacy and safety of cisplatin-based chemotherapy with or without bevacizumab (BEV) in Chinese women with advanced cervical cancer (ACC).
Xiaoli He, Jun Liu, Li Xiao, Mingdong Zhao, Tingting Su, Tiejian Liu, Guowei Han, Yue Wang   +7 more
doaj   +1 more source

Overall Progression Free Survival.

, 2016
Overall Progression Free Survival.
Vipul Doshi (3123906), Vijay M Patil (3123912), Subhadha Kane (3123915), Arvind Sahu (3123900), Amit Joshi (404666), Rajiv Kumar (117613), Kumar Prabhash (404662), Anant Ramaswamy (3123918), Vanita Noronha (404661), Abhishek Mahajan (3123903), Lingaraj Nayak (3123909), Amit Janu (3123897), Anuradha Chougule (404664)   +12 more
core   +1 more source

From junk to function — How weak selection in eukaryotes builds new parts and drives genomic complexity

FEBS Letters, EarlyView.
How do genomes gain new functional parts? In eukaryotes, which tend to evolve under weak selection, much of the genome is junk. Palazzo and Qiu borrow the logic of Markov chains to show how non‐functional DNA becomes functional through the appearance of intermediate states, which arise due to epistasis, buffering, and biochemical messiness, allowing ...
Alexander F. Palazzo, Yi Qiu
wiley   +1 more source

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer

Annals of Thoracic Medicine, 2015
Objectives: The effects of first-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies in patients with small cell lung cancer (SCLC).
Hisao Imai, Keita Mori, Kazushige Wakuda, Akira Ono, Hiroaki Akamatsu, Takehito Shukuya, Tetsuhiko Taira, Hirotsugu Kenmotsu, Tateaki Naito, Kyoichi Kaira, Haruyasu Murakami, Masahiro Endo, Takashi Nakajima, Nobuyuki Yamamoto, Toshiaki Takahashi   +14 more
doaj   +1 more source

Median progression-free survival.

, 2019
Median progression-free survival.
Tristan M. Sissung (220741), Arlene Berman (6410921), Gideon M. Blumenthal (6410918), Arun Rajan (399950), Giuseppe Giaccone (62965), Seth M. Steinberg (202367), David J. Liewehr (202365), William D. Figg (220748)   +7 more
core   +1 more source

Chiral separation of chloroalkanes with the chromatographic column onboard Martian rovers

FEBS Letters, EarlyView.
Computer image of the Rosalind Franklin Rover of ESA's ExoMars mission. ExoMars is scheduled to land on planet Mars in Oxia Planum in 2029. This area represents an interesting spot to look for biosignatures. Investigations of ExoMars include measurement on molecular chirality. We show that chiral chloroalkanes, that have been identified on Mars, can be
Asma Merzougui, Agnes Banreti, Armelle L. Ernst, Guillaume Leseigneur, Uwe J. Meierhenrich   +4 more
wiley   +1 more source

Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women

BMC Gastroenterology, 2019
Background Capecitabine plus bevacizumab (CAP-B) maintenance treatment after 6 cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOXB) has demonstrated clinical activity and failure to compromise quality of life in patients with metastatic ...
Jinsong Su, Jiajie Lai, Ruikun Yang, Bo Xu, Ying Zhu, Mingdong Zhao, Chen Yang, Guanzhao Liang   +7 more
doaj   +1 more source

Progression-free survival with successive suppression and reintroduction of the studies, one-by-one (jackknife).

, 2019
Progression-free survival with successive suppression and reintroduction of the studies, one-by-one (jackknife).
Giuseppe Luigi Banna (6593093), Jean-Pierre Daurès (7288886), Jean-Louis Pujol (748145), Aude Guillou (7288883), Manlio Mencoboni (7288874), Amandine Coffy (5570636), Andrea Camerini (7288871), Epaminontas Samantas (53834), Milena Gusella (735350), Athanasios Kotsakis (74454), Aldo Pezzuto (7288877), Felice Pasini (735351), Benoît Roch (5285813), Cemil Bilir (7288880), Fabrice Barlesi (5653306)   +14 more
core   +1 more source

Multivariate analysis, overall & progression-free survival.

, 2022
Multivariate analysis, overall & progression-free survival.
Nina Jehanno (11949663), Pierre Payoux (3484706), Daniel Orbach (11949669), Marie-Pierre Castex (11949666), Thomas Mognetti (582844), Corradini Nadège (11949672), Helio Fayolle (11949660), Anne Hitzel (11949675), Valerie Lauwers-Cances (437048)   +8 more
core   +1 more source